[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f8KZeQypyUFAV3WBKb6mfHAQxY7LLKQ11-Y7cKoo3cqg":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":39,"rows":46},"Vrije Universiteit Brussel",[4],150,false,38,1,24506,2,142,[14,17,20,22,25,27,29,31],{"name":15,"count":16},"Stroke",20,{"name":18,"count":19},"Healthy",10,{"name":21,"count":19},"Mental Fatigue",{"name":23,"count":24},"Sarcopenia",4,{"name":26,"count":24},"Fatigue",{"name":28,"count":24},"Lower Limb Amputation Above Knee (Injury)",{"name":30,"count":24},"Fibromyalgia",{"name":32,"count":24},"Chronic Low Back Pain",[34],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT05880342","The Role of the Brain in Mental and Physical Fatigue","2025-12-31","Reboxetine Pill",[40,41,42,43,44,45],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[47,70,88,114,132,162,180,210,228,246,264,282,321,349,367,385,403],{"intervention":38,"totalTrials":9,"cells":48},{"EARLY_PHASE1":49,"PHASE1":52,"PHASE2":54,"PHASE3":56,"PHASE4":66,"NA":68},{"trials":50,"activeCount":51},[],0,{"trials":53,"activeCount":51},[],{"trials":55,"activeCount":51},[],{"trials":57,"activeCount":9,"soonestReadout":37},[58],{"nctId":35,"briefTitle":36,"status":59,"phases":60,"primaryCompletion":37,"completion":37,"start":61,"enrollment":62,"conditions":63,"interventions":64},"RECRUITING",[43],"2023-05-03",62,[26],[38,65],"Methylphenidate Oral Product",{"trials":67,"activeCount":51},[],{"trials":69,"activeCount":51},[],{"intervention":65,"totalTrials":9,"cells":71},{"EARLY_PHASE1":72,"PHASE1":74,"PHASE2":76,"PHASE3":78,"PHASE4":84,"NA":86},{"trials":73,"activeCount":51},[],{"trials":75,"activeCount":51},[],{"trials":77,"activeCount":51},[],{"trials":79,"activeCount":9,"soonestReadout":37},[80],{"nctId":35,"briefTitle":36,"status":59,"phases":81,"primaryCompletion":37,"completion":37,"start":61,"enrollment":62,"conditions":82,"interventions":83},[43],[26],[38,65],{"trials":85,"activeCount":51},[],{"trials":87,"activeCount":51},[],{"intervention":89,"totalTrials":9,"cells":90},"OPHTESIC LIDOCAINE HYDROCHLORIDE 20MG\u002FG",{"EARLY_PHASE1":91,"PHASE1":93,"PHASE2":95,"PHASE3":97,"PHASE4":99,"NA":112},{"trials":92,"activeCount":51},[],{"trials":94,"activeCount":51},[],{"trials":96,"activeCount":51},[],{"trials":98,"activeCount":51},[],{"trials":100,"activeCount":51},[101],{"nctId":102,"briefTitle":103,"status":104,"phases":105,"primaryCompletion":37,"completion":37,"start":106,"enrollment":107,"conditions":108,"interventions":110},"NCT05978687","The Use of Lidocaine Gel Versus Subconjunctival Xylocaine Injection in Pterygium Excision","COMPLETED",[44],"2023-09-01",41,[109],"Pterygium",[89,111],"Xylocaine with Epinephrine",{"trials":113,"activeCount":51},[],{"intervention":111,"totalTrials":9,"cells":115},{"EARLY_PHASE1":116,"PHASE1":118,"PHASE2":120,"PHASE3":122,"PHASE4":124,"NA":130},{"trials":117,"activeCount":51},[],{"trials":119,"activeCount":51},[],{"trials":121,"activeCount":51},[],{"trials":123,"activeCount":51},[],{"trials":125,"activeCount":51},[126],{"nctId":102,"briefTitle":103,"status":104,"phases":127,"primaryCompletion":37,"completion":37,"start":106,"enrollment":107,"conditions":128,"interventions":129},[44],[109],[89,111],{"trials":131,"activeCount":51},[],{"intervention":133,"totalTrials":9,"cells":134},"Lidocaine-Adrenaline-Tetracaine (LAT) Gel",{"EARLY_PHASE1":135,"PHASE1":137,"PHASE2":139,"PHASE3":141,"PHASE4":143,"NA":160},{"trials":136,"activeCount":51},[],{"trials":138,"activeCount":51},[],{"trials":140,"activeCount":51},[],{"trials":142,"activeCount":51},[],{"trials":144,"activeCount":51},[145],{"nctId":146,"briefTitle":147,"status":104,"phases":148,"primaryCompletion":149,"completion":150,"start":151,"enrollment":152,"conditions":153,"interventions":158},"NCT07480135","Pain Experience Using Lidocaine Adrenaline Tetracaine (LAT) Gel Versus Lidocaine Infiltration for Laceration Repair in Adults",[44],"2021-05-22","2021-05-31","2021-04-01",70,[154,155,156,157],"Lacerations","Wound Repair","Acute Traumatic Wounds","Pain Management",[133,159],"Lidocaine infiltration",{"trials":161,"activeCount":51},[],{"intervention":159,"totalTrials":9,"cells":163},{"EARLY_PHASE1":164,"PHASE1":166,"PHASE2":168,"PHASE3":170,"PHASE4":172,"NA":178},{"trials":165,"activeCount":51},[],{"trials":167,"activeCount":51},[],{"trials":169,"activeCount":51},[],{"trials":171,"activeCount":51},[],{"trials":173,"activeCount":51},[174],{"nctId":146,"briefTitle":147,"status":104,"phases":175,"primaryCompletion":149,"completion":150,"start":151,"enrollment":152,"conditions":176,"interventions":177},[44],[154,155,156,157],[133,159],{"trials":179,"activeCount":51},[],{"intervention":181,"totalTrials":9,"cells":182},"Intravenous acetazolamide 500 mg OD",{"EARLY_PHASE1":183,"PHASE1":185,"PHASE2":187,"PHASE3":189,"PHASE4":191,"NA":208},{"trials":184,"activeCount":51},[],{"trials":186,"activeCount":51},[],{"trials":188,"activeCount":51},[],{"trials":190,"activeCount":51},[],{"trials":192,"activeCount":51},[193],{"nctId":194,"briefTitle":195,"status":104,"phases":196,"primaryCompletion":197,"completion":197,"start":198,"enrollment":199,"conditions":200,"interventions":203},"NCT05411991","Diuretic Treatment in Acute Heart Failure With Volume Overload Guided by Serial Spot Urine Sodium Assessment",[44],"2024-07-01","2022-06-12",107,[201,202],"Acute Heart Failure","Diuretics Drug Reactions",[181,204,205,206,207],"Intravenous bumetanide TID","Oral chlorthalidone OD","Intravenous canrenoate 200 mg OD","Oral potassium supplements",{"trials":209,"activeCount":51},[],{"intervention":204,"totalTrials":9,"cells":211},{"EARLY_PHASE1":212,"PHASE1":214,"PHASE2":216,"PHASE3":218,"PHASE4":220,"NA":226},{"trials":213,"activeCount":51},[],{"trials":215,"activeCount":51},[],{"trials":217,"activeCount":51},[],{"trials":219,"activeCount":51},[],{"trials":221,"activeCount":51},[222],{"nctId":194,"briefTitle":195,"status":104,"phases":223,"primaryCompletion":197,"completion":197,"start":198,"enrollment":199,"conditions":224,"interventions":225},[44],[201,202],[181,204,205,206,207],{"trials":227,"activeCount":51},[],{"intervention":205,"totalTrials":9,"cells":229},{"EARLY_PHASE1":230,"PHASE1":232,"PHASE2":234,"PHASE3":236,"PHASE4":238,"NA":244},{"trials":231,"activeCount":51},[],{"trials":233,"activeCount":51},[],{"trials":235,"activeCount":51},[],{"trials":237,"activeCount":51},[],{"trials":239,"activeCount":51},[240],{"nctId":194,"briefTitle":195,"status":104,"phases":241,"primaryCompletion":197,"completion":197,"start":198,"enrollment":199,"conditions":242,"interventions":243},[44],[201,202],[181,204,205,206,207],{"trials":245,"activeCount":51},[],{"intervention":206,"totalTrials":9,"cells":247},{"EARLY_PHASE1":248,"PHASE1":250,"PHASE2":252,"PHASE3":254,"PHASE4":256,"NA":262},{"trials":249,"activeCount":51},[],{"trials":251,"activeCount":51},[],{"trials":253,"activeCount":51},[],{"trials":255,"activeCount":51},[],{"trials":257,"activeCount":51},[258],{"nctId":194,"briefTitle":195,"status":104,"phases":259,"primaryCompletion":197,"completion":197,"start":198,"enrollment":199,"conditions":260,"interventions":261},[44],[201,202],[181,204,205,206,207],{"trials":263,"activeCount":51},[],{"intervention":207,"totalTrials":9,"cells":265},{"EARLY_PHASE1":266,"PHASE1":268,"PHASE2":270,"PHASE3":272,"PHASE4":274,"NA":280},{"trials":267,"activeCount":51},[],{"trials":269,"activeCount":51},[],{"trials":271,"activeCount":51},[],{"trials":273,"activeCount":51},[],{"trials":275,"activeCount":51},[276],{"nctId":194,"briefTitle":195,"status":104,"phases":277,"primaryCompletion":197,"completion":197,"start":198,"enrollment":199,"conditions":278,"interventions":279},[44],[201,202],[181,204,205,206,207],{"trials":281,"activeCount":51},[],{"intervention":283,"totalTrials":11,"cells":284},"Citalopram",{"EARLY_PHASE1":285,"PHASE1":287,"PHASE2":289,"PHASE3":291,"PHASE4":293,"NA":295},{"trials":286,"activeCount":51},[],{"trials":288,"activeCount":51},[],{"trials":290,"activeCount":51},[],{"trials":292,"activeCount":51},[],{"trials":294,"activeCount":51},[],{"trials":296,"activeCount":51},[297,308],{"nctId":298,"briefTitle":299,"status":104,"phases":300,"primaryCompletion":301,"completion":301,"start":302,"enrollment":303,"conditions":304,"interventions":306},"NCT01601912","Unraveling the Nature of Impaired Pain Inhibition in Patients With Chronic Whiplash-associated Disorders",[],"2013-12","2013-02",59,[305],"Whiplash Injuries",[307,283],"Atomoxetine",{"nctId":309,"briefTitle":310,"status":311,"phases":312,"primaryCompletion":313,"start":314,"enrollment":152,"conditions":315,"interventions":318},"NCT01154647","Pain Inhibition in Patients With Rheumatoid Arthritis and Central Sensitivity Syndromes","UNKNOWN",[45],"2012-09","2010-09",[316,30,317],"Fatigue Syndrome, Chronic","Arthritis, Rheumatoid",[319,320],"citalopram","1 ml 0.9 % NaCl",{"intervention":322,"totalTrials":9,"cells":323},"single embryo transfer without aneuploidy screening",{"EARLY_PHASE1":324,"PHASE1":326,"PHASE2":328,"PHASE3":330,"PHASE4":332,"NA":334},{"trials":325,"activeCount":51},[],{"trials":327,"activeCount":51},[],{"trials":329,"activeCount":51},[],{"trials":331,"activeCount":51},[],{"trials":333,"activeCount":51},[],{"trials":335,"activeCount":51},[336],{"nctId":337,"briefTitle":338,"status":339,"phases":340,"primaryCompletion":341,"completion":342,"start":343,"enrollment":344,"conditions":345,"interventions":347},"NCT00670059","Pre-Implantation Genetic Screening in Women Under the Age of 36 Years With Single Embryo Transfer","TERMINATED",[45],"2007-06","2008-02","2004-10",240,[346],"Live Birth Delivery Rate",[322,348],"single embryo transfer with aneuploidy screening",{"intervention":348,"totalTrials":9,"cells":350},{"EARLY_PHASE1":351,"PHASE1":353,"PHASE2":355,"PHASE3":357,"PHASE4":359,"NA":361},{"trials":352,"activeCount":51},[],{"trials":354,"activeCount":51},[],{"trials":356,"activeCount":51},[],{"trials":358,"activeCount":51},[],{"trials":360,"activeCount":51},[],{"trials":362,"activeCount":51},[363],{"nctId":337,"briefTitle":338,"status":339,"phases":364,"primaryCompletion":341,"completion":342,"start":343,"enrollment":344,"conditions":365,"interventions":366},[45],[346],[322,348],{"intervention":307,"totalTrials":9,"cells":368},{"EARLY_PHASE1":369,"PHASE1":371,"PHASE2":373,"PHASE3":375,"PHASE4":377,"NA":379},{"trials":370,"activeCount":51},[],{"trials":372,"activeCount":51},[],{"trials":374,"activeCount":51},[],{"trials":376,"activeCount":51},[],{"trials":378,"activeCount":51},[],{"trials":380,"activeCount":51},[381],{"nctId":298,"briefTitle":299,"status":104,"phases":382,"primaryCompletion":301,"completion":301,"start":302,"enrollment":303,"conditions":383,"interventions":384},[],[305],[307,283],{"intervention":320,"totalTrials":9,"cells":386},{"EARLY_PHASE1":387,"PHASE1":389,"PHASE2":391,"PHASE3":393,"PHASE4":395,"NA":397},{"trials":388,"activeCount":51},[],{"trials":390,"activeCount":51},[],{"trials":392,"activeCount":51},[],{"trials":394,"activeCount":51},[],{"trials":396,"activeCount":51},[],{"trials":398,"activeCount":51},[399],{"nctId":309,"briefTitle":310,"status":311,"phases":400,"primaryCompletion":313,"start":314,"enrollment":152,"conditions":401,"interventions":402},[45],[316,30,317],[319,320],{"intervention":404,"totalTrials":9,"cells":405},"Exposure to COVID-19",{"EARLY_PHASE1":406,"PHASE1":408,"PHASE2":410,"PHASE3":412,"PHASE4":414,"NA":416},{"trials":407,"activeCount":51},[],{"trials":409,"activeCount":51},[],{"trials":411,"activeCount":51},[],{"trials":413,"activeCount":51},[],{"trials":415,"activeCount":51},[],{"trials":417,"activeCount":51},[418],{"nctId":419,"briefTitle":420,"status":104,"phases":421,"primaryCompletion":422,"completion":422,"start":423,"enrollment":424,"conditions":425,"interventions":430},"NCT04726176","COVID-19 and the Brain",[],"2021-12-01","2021-01-30",40,[426,427,428,429],"Covid19","Brain","Neurocognition","fMRI",[404]]